Regarding the new coronavirus vaccine under development, Daiichi Sankyo, a major pharmaceutical company, announced that the results of the final stage clinical trial confirmed that it was as effective as the vaccines of Pfizer and Moderna for the third inoculation. Did.
We are preparing to apply for approval to the government in January next year as a vaccine for booster vaccination.
Daiichi Sankyo is developing a domestic new coronavirus messenger RNA = mRNA vaccine with its own technology.
According to the company's announcement, a final-stage clinical trial was conducted on approximately 5,000 people aged 18 and over, assuming the third vaccination, and after two doses of Pfizer and Moderna mRNA vaccines, Daiichi Sankyo At 4 weeks after vaccination, those who received the vaccine under development had a higher degree of increase in neutralizing antibodies that suppress the action of the virus than those who received booster vaccines from Pfizer and Moderna.
The company says it was as effective as previous vaccines and had no safety issues.
When developing an mRNA vaccine for the new corona, the government requires confirmation of the same level of efficacy as that used so far, and confirmation of safety in at least 3,000 people. Based on this result, Daiichi Sankyo is preparing to apply for approval to the government in January next year as a booster vaccination.